Cargando…

Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors

Genetic modification of many types of mouse tumors to express the B7-1 or B7-2 molecules, natural ligands for the T cell-costimulatory molecule CD28, increases their immunogenicity. However, even after transfection with the B7-1 and/or B7-2 genes, poorly immunogenic tumors fail to elicit and efficie...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192440/
https://www.ncbi.nlm.nih.gov/pubmed/8627175
_version_ 1782147240429617152
collection PubMed
description Genetic modification of many types of mouse tumors to express the B7-1 or B7-2 molecules, natural ligands for the T cell-costimulatory molecule CD28, increases their immunogenicity. However, even after transfection with the B7-1 and/or B7-2 genes, poorly immunogenic tumors fail to elicit and efficient immune response. We report here that two such tumors, the Ag104A sarcoma and the K1735-M2 melanoma, become immunogenic after transfection of the genes encoding murine B7-1 together with CD48, which is the natural ligand for CD2. Tumor-specific CD8+ cytotoxic T lymphocytes were readily generated and were effective for adoptive immunotherapy of metastasis induced by wild-type Ag104A sarcoma cells. A similar approach may be useful for developing therapy for other poorly immunogenic tumors, including those in humans.
format Text
id pubmed-2192440
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21924402008-04-16 Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors J Exp Med Articles Genetic modification of many types of mouse tumors to express the B7-1 or B7-2 molecules, natural ligands for the T cell-costimulatory molecule CD28, increases their immunogenicity. However, even after transfection with the B7-1 and/or B7-2 genes, poorly immunogenic tumors fail to elicit and efficient immune response. We report here that two such tumors, the Ag104A sarcoma and the K1735-M2 melanoma, become immunogenic after transfection of the genes encoding murine B7-1 together with CD48, which is the natural ligand for CD2. Tumor-specific CD8+ cytotoxic T lymphocytes were readily generated and were effective for adoptive immunotherapy of metastasis induced by wild-type Ag104A sarcoma cells. A similar approach may be useful for developing therapy for other poorly immunogenic tumors, including those in humans. The Rockefeller University Press 1996-02-01 /pmc/articles/PMC2192440/ /pubmed/8627175 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors
title Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors
title_full Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors
title_fullStr Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors
title_full_unstemmed Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors
title_short Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors
title_sort costimulation by cd48 and b7-1 induces immunity against poorly immunogenic tumors
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192440/
https://www.ncbi.nlm.nih.gov/pubmed/8627175